[{"orgOrder":0,"company":"Mosaic ImmunoEngineering","sponsor":"University of California San Diego","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the University of California San Diego","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Mosaic ImmunoEngineering","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Mosaic ImmunoEngineering","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncotelic Therapeutics, Inc. to Sell its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Mosaic ImmunoEngineering
Through the acquisition, the company will utilize OT-101 (trabedersen), currently under investigation in mid-stage clinical trials with adult patients, for treating brain cancer and diffuse intrinsic pontine glioma.
MIE-101, a Cowpea mosaic virus has shown to engage multiple Toll-like receptors on host immune cells in the tumor that have evolved to detect foreign invaders enhanced antitumor effects when combined with immune checkpoint inhibitors and other standard cancer therapies.
Under the agreement, Mosaic has licensed rights to develop and commercialize new treatment candidates including lead product, MIE-101, is derived from the cowpea mosaic virus (CPMV), that broaden the scope and capabilities of the protein nanoparticle platform to treat cancer.